[Estimated prevalence rate of HTLV-I uveitis in Chikugo]
- PMID: 9619025
[Estimated prevalence rate of HTLV-I uveitis in Chikugo]
Abstract
To estimate the prevalence rate of human T-cell lymphotropic virus type 1 (HTLV-I) uveitis, an epidemiological survey was carried out in the Chikugo District of Fukuoka Prefecture between 1 September and 31 October 1995. The survey was done by sending questionnaires on uveitis patients to all ophthalmological institutes in the district and measuring the serum antibody to HTLV-I. The recovery rate of the survey was 39 of 48 institutes (81.3%). A total of 357 patients with uveitis were reported in the survey, of whom 317 (88.8%) were tested for their seropositivity to HTLV-I. Among them, 18 patients were counted as having HTLV-I uveitis (HU) on 1 October 1995. Based on these data together with the age- and sex-specific population of HTLV-I carriers in the Chikugo District, it was estimated that the crude prevalence rates of HU per 100,000 HTLV-I carrier population were 58.6 in males, 152.0 in females, and 112.2 in both sexes. The prevalence rate of HU was slightly higher than that of HTLV-I associated myelopathy.
Similar articles
-
[Prevalence of endogenous uveitis in Kagoshima Prefecture, Southwest Japan].Nippon Ganka Gakkai Zasshi. 1996 Feb;100(2):150-5. Nippon Ganka Gakkai Zasshi. 1996. PMID: 8851155 Japanese.
-
[Uveitis in human T-lymphotropic virus type I (HTLV-I) carriers--1. A seroepidemiological study].Nippon Ganka Gakkai Zasshi. 1993 Jun;97(6):726-32. Nippon Ganka Gakkai Zasshi. 1993. PMID: 8328341 Japanese.
-
HTLV-I seroprevalence in patients with undefined uveitis in central Japan.Jpn J Ophthalmol. 1994;38(2):175-7. Jpn J Ophthalmol. 1994. PMID: 7967209
-
Epidemiology of Uveitis, Caused by HTLV-1, Toxoplasmosis, and Tuberculosis; the Three Leading Causes of Endemic Infectious Uveitis in Japan.Ocul Immunol Inflamm. 2017;25(sup1):S19-S23. doi: 10.1080/09273948.2016.1253851. Epub 2016 Dec 7. Ocul Immunol Inflamm. 2017. PMID: 27925851 Review.
-
Tropical spastic paraparesis and HTLV-1 associated myelopathy: clinical, epidemiological, virological and therapeutic aspects.Rev Neurol (Paris). 2012 Mar;168(3):257-69. doi: 10.1016/j.neurol.2011.12.006. Epub 2012 Mar 7. Rev Neurol (Paris). 2012. PMID: 22405461 Review.
Cited by
-
Development of a Monoclonal Antibody Targeting HTLV-1 Envelope gp46 Glycoprotein and Its Application to Near-Infrared Photoimmuno-Antimicrobial Strategy.Viruses. 2022 Sep 29;14(10):2153. doi: 10.3390/v14102153. Viruses. 2022. PMID: 36298708 Free PMC article.
-
Clinical Features and Possible Origin of Preretinal Deposits in Different Ocular Diseases and Events: A Narrative Review.Ophthalmol Ther. 2023 Apr;12(2):737-753. doi: 10.1007/s40123-023-00674-4. Epub 2023 Feb 16. Ophthalmol Ther. 2023. PMID: 36795322 Free PMC article. Review.
-
Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan.Orphanet J Rare Dis. 2019 Oct 21;14(1):227. doi: 10.1186/s13023-019-1212-4. Orphanet J Rare Dis. 2019. PMID: 31639014 Free PMC article.
-
Prevalence and characteristics of HTLV-associated uveitis in patients from Bahia, an endemic area for HTLV - 1 in Brazil.Virol J. 2023 Aug 21;20(1):185. doi: 10.1186/s12985-023-02135-7. Virol J. 2023. PMID: 37605273 Free PMC article.
-
Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis.Int J Mol Sci. 2024 Mar 12;25(6):3229. doi: 10.3390/ijms25063229. Int J Mol Sci. 2024. PMID: 38542203 Free PMC article.